Evaxion Biotech A/S (Nasdaq: EVAX) announced encouraging findings from its EVX-01 Phase 1 clinical trial, which assessed the safety and effectiveness of EVX-01 in combination with a checkpoint inhibitor for metastatic melanoma patients. 

According to Evaxion, the trial successfully met its primary goals, demonstrating the safety and tolerability of the personalized cancer vaccine EVX-01. Notably, 8 out of 12 patients treated with EVX-01 showed positive clinical responses. Additionally, all 12 patients exhibited strong vaccine-specific immune responses, with higher doses of EVX-01 correlating with improved clinical outcomes.

Evaxion's AI technology, PIONEER, played a crucial role in identifying high-quality cancer vaccine targets known as neoantigens, which were associated with longer progression-free survival. 

On Friday, $EVAX closed at $1.48, down $0.06 (3.90%).

Celsius Holdings, Inc. (Nasdaq: CELH), a leading global fitness beverage company, received a price target increase from $130 to $160 by UBS. 

With $CELH closing at $138.17 on Friday, this adjustment suggests a potential upside of $21.83 (15.78%) based on the brokerage firm's view.

Accenture plc (NYSE: ACN), a multinational professional services company, saw its price target raised from $325 to $350 by Morgan Stanley. 

With $ACN closing at $311.39 on Friday, this adjustment indicates a potential upside of $38.61 (12.40%) as per the investment firm's analysis.

Five Below, Inc. (Nasdaq: FIVE), a specialty retailer offering trendy merchandise for teens and pre-teens, witnessed a price target increase from $238 to $239 by Deutsche Bank. 

With Friday's closing price at $182.55, this adjustment suggests a potential upside of $56.45 (30.92%) for $FIVE, based on the analysts' view.

It is important to note that the potential upsides mentioned earlier are derived from the perspectives of the respective brokerage firm, investment firm, or analysts. These estimates are subject to market fluctuations and should be considered in conjunction with individual investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)